TY - JOUR
T1 - Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response
AU - Tintle, Suzanne
AU - Shemer, Avner
AU - Suárez-Fariñas, Mayte
AU - Fujita, Hideki
AU - Gilleaudeau, Patricia
AU - Sullivan-Whalen, Mary
AU - Johnson-Huang, Leanne
AU - Chiricozzi, Andrea
AU - Cardinale, Irma
AU - Duan, Shenghui
AU - Bowcock, Anne
AU - Krueger, James G.
AU - Guttman-Yassky, Emma
N1 - Funding Information:
Supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR) , a component of the National Institutes of Health (NIH) , and the NIH Roadmap for Medical Research. S. T. and E. G.-Y. were supported by a Clinical and Translational Science Award grant, and E. G.-Y. was also supported by a Women’s Dermatology Society grant and a physician scientist career development award from the Dermatology Foundation.
PY - 2011/9
Y1 - 2011/9
N2 - Background: Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly TH2/"T22" immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate-to-severe AD. In patients with psoriasis, NB-UVB has been found to suppress TH1/TH17 polarization, with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in patients with AD. Objective: We sought to evaluate the effects of NB-UVB on immune and barrier abnormalities in patients with AD, aiming to establish reversibility of disease and biomarkers of therapeutic response. Methods: Twelve patients with moderate-to-severe chronic AD received NB-UVB phototherapy 3 times weekly for up to 12 weeks. Lesional and nonlesional skin biopsy specimens were obtained before and after treatment and evaluated by using gene expression and immunohistochemistry studies. Results: All patients had at least a 50% reduction in SCORAD index scores with NB-UVB phototherapy. The TH2, T22, and TH1 immune pathways were suppressed, and measures of epidermal hyperplasia and differentiation normalized. The reversal of disease activity was associated with elimination of inflammatory leukocytes and TH2/T22- associated cytokines and chemokines and normalized expression of barrier proteins. Conclusions: Our study shows that resolution of clinical disease in patients with chronic AD is accompanied by reversal of both the epidermal defects and the underlying immune activation. We have defined a set of biomarkers of disease response that associate resolved TH2 and T22 inflammation in patients with chronic AD with reversal of barrier pathology. By showing reversal of the AD epidermal phenotype with a broad immune-targeted therapy, our data argue against a fixed genetic phenotype.
AB - Background: Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly TH2/"T22" immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate-to-severe AD. In patients with psoriasis, NB-UVB has been found to suppress TH1/TH17 polarization, with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in patients with AD. Objective: We sought to evaluate the effects of NB-UVB on immune and barrier abnormalities in patients with AD, aiming to establish reversibility of disease and biomarkers of therapeutic response. Methods: Twelve patients with moderate-to-severe chronic AD received NB-UVB phototherapy 3 times weekly for up to 12 weeks. Lesional and nonlesional skin biopsy specimens were obtained before and after treatment and evaluated by using gene expression and immunohistochemistry studies. Results: All patients had at least a 50% reduction in SCORAD index scores with NB-UVB phototherapy. The TH2, T22, and TH1 immune pathways were suppressed, and measures of epidermal hyperplasia and differentiation normalized. The reversal of disease activity was associated with elimination of inflammatory leukocytes and TH2/T22- associated cytokines and chemokines and normalized expression of barrier proteins. Conclusions: Our study shows that resolution of clinical disease in patients with chronic AD is accompanied by reversal of both the epidermal defects and the underlying immune activation. We have defined a set of biomarkers of disease response that associate resolved TH2 and T22 inflammation in patients with chronic AD with reversal of barrier pathology. By showing reversal of the AD epidermal phenotype with a broad immune-targeted therapy, our data argue against a fixed genetic phenotype.
KW - Atopic dermatitis
KW - T22
KW - biomarker
KW - narrow-band UVB
KW - phototherapy
KW - skin
UR - http://www.scopus.com/inward/record.url?scp=80052265685&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2011.05.042
DO - 10.1016/j.jaci.2011.05.042
M3 - Article
AN - SCOPUS:80052265685
SN - 0091-6749
VL - 128
SP - 583-593.e4
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3
ER -